Cargando…
Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer
OBJECTIVE: Adjuvant Chemotherapy Trial of TS-1 for Colon Cancer (ACTS-CC), a randomised phase III trial, demonstrated that adjuvant therapy with S-1 for stage III colon cancer was non-inferior in 3-year disease-free survival (DFS) to that of tegafur-uracil plus leucovorin (UFT/LV). We updated DFS an...
Autores principales: | Kusumoto, Tetsuya, Ishiguro, Megumi, Nakatani, Eiji, Yoshida, Motoki, Inoue, Tsukasa, Nakamoto, Yoshihiko, Shiomi, Akio, Takagane, Akinori, Sunami, Eiji, Shinozaki, Hiroharu, Takii, Yasumasa, Maeda, Atsuyuki, Ojima, Hitoshi, Hashida, Hiroki, Mukaiya, Mitsuhiro, Yokoyama, Tadashi, Nakamura, Masato, Munemoto, Yoshinori, Sugihara, Kenichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212676/ https://www.ncbi.nlm.nih.gov/pubmed/30425843 http://dx.doi.org/10.1136/esmoopen-2018-000428 |
Ejemplares similares
-
Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
por: Hasegawa, Kiyoshi, et al.
Publicado: (2016) -
A case of successful concomitant administration of warfarin and uracil‐tegafur/leucovorin achieved by self‐measurement of INR
por: Watanabe, Norio, et al.
Publicado: (2017) -
Administration Method of Adjuvant Tegafur‐Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study
por: Hata, Taishi, et al.
Publicado: (2021) -
Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer
por: Yasui, Masayoshi, et al.
Publicado: (2006) -
S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
por: Watanabe, J., et al.
Publicado: (2021)